$APYX
Apyx Medical Corp Stock $apyx

$apyx Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000071913521000036 Filed on May 12, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$8.638M	$4.997M
YoY Change	72.86%	-11.23%
Cost Of Revenue	$2.778M	$2.013M
YoY Change	38.0%	-2.57%
Gross Profit	$5.860M	$2.984M
YoY Change	96.38%	-16.25%
Gross Profit Margin	67.84%	59.72%
Selling, General & Admin	$3.724M	$3.796M
YoY Change	-1.9%	28.37%
% of Gross Profit	63.55%	127.21%
Research & Development	$1.115M	$980.0K
YoY Change	13.78%	34.25%
% of Gross Profit	19.03%	32.84%
Depreciation & Amortization	$227.0K	$214.0K
YoY Change	6.07%	10.31%
% of Gross Profit	3.87%	7.17%
Operating Expenses	$10.61M	$10.48M
YoY Change	1.23%	12.73%
Operating Profit	-$4.745M	-$7.492M
YoY Change	-36.67%	30.75%
Interest Expense	$4.000K	$6.000K
YoY Change	-33.33%
% of Operating Profit
Other Income/Expense, Net	-$94.00K	$636.0K
YoY Change	-114.78%	396.88%
Pretax Income	-$4.839M	-$6.856M
YoY Change	-29.42%	22.38%
Income Tax	$66.00K	-$4.905M
% Of Pretax Income
Net Earnings	-$4.901M	-$1.951M
YoY Change	151.2%	-58.32%
Net Earnings / Revenue	-56.74%	-39.04%
Basic Earnings Per Share	-$0.14
Diluted Earnings Per Share	-$0.14	-$57.05K
COMMON SHARES
Basic Shares Outstanding	34.30M shares	34.17M shares
Diluted Shares Outstanding	34.30M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$39.50M	$51.40M
YoY Change	-23.15%	-29.88%
Cash & Equivalents	$39.54M	$51.38M
Short-Term Investments
Other Short-Term Assets	$2.600M	$4.400M
YoY Change	-40.91%	214.29%
Inventory	$4.463M	$5.872M
Prepaid Expenses
Receivables	$7.683M	$6.122M
Other Receivables	$1.110M	$1.302M
Total Short-Term Assets	$63.04M	$74.17M
YoY Change	-15.0%	-13.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.599M	$6.543M
YoY Change	0.86%	8.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$860.0K	$482.0K
YoY Change	78.42%	38.9%
Total Long-Term Assets	$8.054M	$7.946M
YoY Change	1.36%	21.5%
TOTAL ASSETS
Total Short-Term Assets	$63.04M	$74.17M
Total Long-Term Assets	$8.054M	$7.946M
Total Assets	$71.10M	$82.12M
YoY Change	-13.42%	-10.6%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.283M	$2.535M
YoY Change	-9.94%	68.55%
Accrued Expenses	$5.500M	$7.586M
YoY Change	-27.5%	8.23%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$200.0K	$400.0K
YoY Change	-50.0%
Total Short-Term Liabilities	$9.730M	$10.60M
YoY Change	-8.22%	23.04%
LONG-TERM LIABILITIES
Long-Term Debt	$100.0K	$400.0K
YoY Change	-75.0%	300.0%
Other Long-Term Liabilities	$141.0K	$520.0K
YoY Change	-72.88%	168.04%
Total Long-Term Liabilities	$141.0K	$520.0K
YoY Change	-72.88%	168.04%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.730M	$10.60M
Total Long-Term Liabilities	$141.0K	$520.0K
Total Liabilities	$10.93M	$11.69M
YoY Change	-6.49%	29.48%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.280M	$12.57M
YoY Change	-118.14%	-56.09%
Common Stock	$34.00K	$34.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$60.04M	$70.43M
YoY Change
Total Liabilities & Shareholders Equity	$71.10M	$82.12M
YoY Change	-13.42%	-10.6%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$4.901M	-$1.951M
YoY Change	151.2%	-58.32%
Depreciation, Depletion And Amortization	$227.0K	$214.0K
YoY Change	6.07%	10.31%
Cash From Operating Activities	-$2.052M	-$7.407M
YoY Change	-72.3%	45.55%
INVESTING ACTIVITIES
Capital Expenditures	$192.0K	$90.00K
YoY Change	113.33%	-23.08%
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change		-100.0%
Cash From Investing Activities	-$192.0K	-$90.00K
YoY Change	113.33%	-100.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$61.00K	$15.00K
YoY Change	-506.67%	-77.61%
NET CHANGE
Cash From Operating Activities	-$2.052M	-$7.407M
Cash From Investing Activities	-$192.0K	-$90.00K
Cash From Financing Activities	-$61.00K	$15.00K
Net Change In Cash	-$2.376M	-$7.432M
YoY Change	-68.03%	-146.98%
FREE CASH FLOW
Cash From Operating Activities	-$2.052M	-$7.407M
Capital Expenditures	$192.0K	$90.00K
Free Cash Flow	-$2.244M	-$7.497M
YoY Change	-70.07%	44.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000719135
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	0-12183
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	APYX MEDICAL CORPORATION
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2644611
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	5115 Ulmerton Road,
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Clearwater
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33760
CY2021Q1	dei	City Area Code CityAreaCode	727
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	384-2323
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock
CY2021Q1	dei	Trading Symbol TradingSymbol	APYX
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	34317863	shares
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39539000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41915000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	7683000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	8399000	USD
CY2021Q1	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2020Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	7654000	USD
CY2021Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1110000	USD
CY2020Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	1275000	USD
CY2021Q1	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	374000	USD
CY2020Q4	apyx	Provision For Obsolescence Inventory ProvisionForObsolescenceInventory	388000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	4463000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2593000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2795000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	63042000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	66089000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4985000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4813000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6599000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6541000	USD
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	237000	USD
CY2021Q1	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	383000	USD
CY2020Q4	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	437000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	860000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	807000	USD
CY2021Q1	us-gaap	Assets Assets	71096000	USD
CY2020Q4	us-gaap	Assets Assets	74111000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2283000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1511000	USD
CY2021Q1	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7090000	USD
CY2020Q4	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7278000	USD
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	125000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	126000	USD
CY2021Q1	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	232000	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	238000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9730000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9153000	USD
CY2021Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	94000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	129000	USD
CY2021Q1	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	107000	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	183000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	855000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	621000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	141000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	10927000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	10252000	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34317863	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34317863	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	34289222	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	34289222	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	34000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62281000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	61066000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2280000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	2621000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	60035000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	63721000	USD
CY2021Q1	us-gaap	Minority Interest MinorityInterest	134000	USD
CY2020Q4	us-gaap	Minority Interest MinorityInterest	138000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	60169000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	71096000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	74111000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8638000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4997000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2778000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2013000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	5860000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	2984000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1115000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	980000	USD
CY2021Q1	us-gaap	Professional Fees ProfessionalFees	1521000	USD
CY2020Q1	us-gaap	Professional Fees ProfessionalFees	2389000	USD
CY2021Q1	us-gaap	Salaries And Wages SalariesAndWages	4245000	USD
CY2020Q1	us-gaap	Salaries And Wages SalariesAndWages	3311000	USD
CY2021Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3724000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3796000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	10605000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	10476000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4745000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7492000	USD
CY2020Q1	us-gaap	Interest Income Operating InterestIncomeOperating	216000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	6000	USD
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-93000	USD
CY2020Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	426000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-94000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	636000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4839000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6856000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4905000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-4905000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-1951000	USD
CY2021Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-4000	USD
CY2020Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4901000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1951000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	71259000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	72000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1049000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-1951000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	70429000	USD
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	63859000	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1194000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-4905000	USD
CY2021Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	60169000	USD
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-4905000	USD
CY2020Q1	us-gaap	Profit Loss ProfitLoss	-1951000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	227000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	214000	USD
CY2021Q1	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	0	USD
CY2020Q1	apyx	Provision For Inventory Obsolescence ProvisionForInventoryObsolescence	10000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1194000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	1049000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	6000	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	324000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-680000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1520000	USD
CY2021Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	0	USD
CY2020Q1	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	4641000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-312000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1383000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	372000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	855000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	782000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	107000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	24000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1801000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2052000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7407000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	192000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	90000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-192000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-90000	USD
CY2021Q1	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	21000	USD
CY2020Q1	apyx	Proceeds From Stock Options Exercised And Warrants Exercised ProceedsFromStockOptionsExercisedAndWarrantsExercised	72000	USD
CY2021Q1	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	82000	USD
CY2020Q1	apyx	Repaymentof Finance Lease Liabilities RepaymentofFinanceLeaseLiabilities	57000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-61000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	15000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-71000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50000	USD
CY2021Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	891000	USD
CY2020Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1109000	USD
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2243000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2376000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7432000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	41915000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	58812000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	39539000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	51380000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	4000	USD
CY2020Q1	us-gaap	Interest Paid Net InterestPaidNet	6000	USD
CY2021Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2020Q1	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021Q1	us-gaap	Description Of New Accounting Pronouncements Not Yet Adopted DescriptionOfNewAccountingPronouncementsNotYetAdopted	RECENT ACCOUNTING PRONOUNCEMENTS <div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments—Credit Losses (Topic 326).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company currently expects to continue to qualify as a Smaller Reporting Company, based upon the current SEC definition, and as a result, will be utilizing the deferred elective date. While we are in the process of determining the effects of the adoption of the standard on the consolidated financial statements, we do not expect the impact to be material.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.</span></div>
CY2018Q3	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	97000000	USD
CY2021Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	2515000	USD
CY2021Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1431000	USD
CY2020Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1087000	USD
CY2021Q1	us-gaap	Inventory Gross InventoryGross	4837000	USD
CY2020Q4	us-gaap	Inventory Gross InventoryGross	4439000	USD
CY2021Q1	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	374000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	388000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	4463000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	4051000	USD
CY2021Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	740000	USD
CY2021Q1	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	866000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	808000	USD
CY2021Q1	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	413000	USD
CY2020Q4	us-gaap	Accrued Bonuses Current AccruedBonusesCurrent	811000	USD
CY2021Q1	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	748000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1001000	USD
CY2021Q1	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	510000	USD
CY2020Q4	us-gaap	Product Warranty Accrual Classified Current ProductWarrantyAccrualClassifiedCurrent	498000	USD
CY2021Q1	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	329000	USD
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	435000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	297000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	222000	USD
CY2021Q1	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2020Q4	apyx	Joint And Several Payroll Liability JointAndSeveralPayrollLiability	1027000	USD
CY2021Q1	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1707000	USD
CY2020Q4	apyx	Uncertain Tax Positions Liability UncertainTaxPositionsLiability	1658000	USD
CY2021Q1	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	453000	USD
CY2020Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	591000	USD
CY2020Q4	apyx	Other Accrued Expenses And Liabilities Current OtherAccruedExpensesAndLiabilitiesCurrent	227000	USD
CY2021Q1	apyx	Accrued Liabilities And Other Liabilities Current AccruedLiabilitiesAndOtherLiabilitiesCurrent	7090000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	7278000	USD
CY2019Q4	apyx	Noncontrolling Interest Required Capital Contribution NoncontrollingInterestRequiredCapitalContribution	357000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4901000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-1951000	USD
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	44082	shares
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34302000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34176000	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1194000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1049000	USD
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4938943	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.46
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	700980	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.29
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.25
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	36401	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.47
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5559440	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.93
CY2021Q1	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	15441	shares
CY2020Q1	apyx	Stock Issued During Period Shares Stock Swaps Equity Instruments Received StockIssuedDuringPeriodSharesStockSwapsEquityInstrumentsReceived	1924	shares
CY2021Q1	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	21141	shares
CY2020Q1	apyx	Stock Issued During Period Shares Stock Swaps StockIssuedDuringPeriodSharesStockSwaps	4362	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.29
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.006
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.708
CY2021Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2020	apyx	Cares Act Income Tax Expense Benefit Release Of Valuation Allowance Federal Net Operating Loss Carryforwards CARESActIncomeTaxExpenseBenefitReleaseOfValuationAllowanceFederalNetOperatingLossCarryforwards	-3700000	USD
CY2020Q1	apyx	Cares Act Income Tax Expense Benefit Related To Current Period Net Income Loss Before Income Taxes CARESActIncomeTaxExpenseBenefitRelatedToCurrentPeriodNetIncomeLossBeforeIncomeTaxes	-1200000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4905000	USD
CY2021Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.014
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.715
CY2021Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1313000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	394000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	48000	USD
CY2020Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	43000	USD
CY2021Q1	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	1707000	USD
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	3300000	USD
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2	segment
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8638000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4745000	USD
CY2021Q1	us-gaap	Interest Income Operating InterestIncomeOperating	3000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	4000	USD
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-93000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	66000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4997000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7492000	USD
CY2020Q1	us-gaap	Interest Income Operating InterestIncomeOperating	216000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	6000	USD
CY2020Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	426000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-4905000	USD
CY2021Q1	apyx	Total Revenue Percent TotalRevenuePercent	0.356
CY2020Q1	apyx	Total Revenue Percent TotalRevenuePercent	0.276
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8638000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4997000	USD

Files In Submission

Name	View Source	Status
0000719135-21-000036-index-headers.html	Edgar Link	pending
0000719135-21-000036-index.html	Edgar Link	pending
0000719135-21-000036.txt	Edgar Link	pending
0000719135-21-000036-xbrl.zip	Edgar Link	pending
a2021q110-qexhibit311.htm	Edgar Link	pending
a2021q110-qexhibit312.htm	Edgar Link	pending
a2021q110-qexhibit321.htm	Edgar Link	pending
a2021q110-qexhibit322.htm	Edgar Link	pending
apyx-20210331.htm	Edgar Link	pending
apyx-20210331.xsd	Edgar Link	pending
apyx-20210331_cal.xml	Edgar Link	unprocessable
apyx-20210331_def.xml	Edgar Link	unprocessable
apyx-20210331_g1.jpg	Edgar Link	pending
apyx-20210331_htm.xml	Edgar Link	completed
apyx-20210331_lab.xml	Edgar Link	unprocessable
apyx-20210331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$APYX
Apyx Medical Corp Stock $apyx

2021 Q1 Form 10-Q Financial Statement

#000071913521000036 Filed on May 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX Apyx Medical Corp Stock $apyx

2021 Q1 Form 10-Q Financial Statement

#000071913521000036 Filed on May 12, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$APYX
Apyx Medical Corp Stock $apyx